(Q51355964)

4 April 2018

title

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. (English)

1 reference

4 April 2018

1 reference

1

Grzegorz Helbig

1 reference

4 April 2018

Slawomira Kyrcz-Krzemien

6

object named as

Sławomira Kyrcz-Krzemień

1 reference

4 April 2018

author name string

Agata Wieczorkiewicz

2

1 reference

4 April 2018

Krzysztof Woźniczka

3

1 reference

4 April 2018

Katarzyna Wiśniewska-Piąty

4

1 reference

4 April 2018

Anna Rusek

5

1 reference

4 April 2018

publication date

1 March 2012

1 reference

4 April 2018

published in

Medical Oncology

1 reference

4 April 2018

volume

29

1 reference

4 April 2018

issue

4

1 reference

4 April 2018

page(s)

2379-2384

1 reference

4 April 2018

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0190-3

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

21 January 2018

1 reference

12 December 2020

Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis

1 reference

12 December 2020

Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.

1 reference

12 December 2020

A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

12 December 2020

10.1007/S12032-012-0190-3

Identifiers

DOI

1 reference

4 April 2018

1 reference

4 April 2018